Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type2 diabetes

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 4022-4029

  Hollander, Priscilla ^a   Gupta, Alok K ^b,c   Plodkowski, Raymond ^d   Greenway, Frank ^b   Bays, Harold ^e   Burns, Colleen ^f   Klassen, Preston ^f   Fujioka, Ken ^d  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c Our Lady of the Lake Medical Center   (United States)

^d SCRIPPS CLINIC   (United States)

^e LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^f Orexigen Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; AGED; BLOOD; COMPLICATION; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; OVERWEIGHT; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; BODY WEIGHT; BUPROPION; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84891869792     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0234     Document Type: Article

References (40)

1. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-368
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307: 491-497
3. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetesd United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004;53:1066-1068
4. Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obes Metab 2010;12:267-287
5. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80
6. Goldstein DJ. Beneficial health effects of modest weight loss. Int JObes Relat Metab Disord 1992;16:397-415
7. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-1486
8. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-1504
9. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
10. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006;6: 1249-1265
11. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-641
12. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-828
13. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17:30-39
14. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-295
15. Sinnayah P, Wallingford NM, Evans AE, Cowley MA. Bupropion and naltrexone interact synergistically to decrease food intake in mice (Abstract). Obesity (Silver Spring) 2007;15:A179
16. Apovian CM, Aronne LJ, Rubino DM, et al.; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21: 935-943
17. Greenway FL, Fujioka K, Plodkowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605
18. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19: 110-120
19. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004;15:124-129
20. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672
21. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
22. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011;57:2461-2473
23. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
24. Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686
25. Lindström J, Louheranta A, Mannelin M, et al.; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-3236
26. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-1294
27. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161
28. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
30. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52: 2288-2298
31. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials. Lancet 2009;373:1765-1772
32. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009;19:604-612
33. Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adipostiy: effects of the naltrexone/bupropion combination on body composition. Diabetes Obes Metab. 12 March 2013 [Epub ahead of print]
34. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000;133:92-103
35. Katsoulis K, Blaudeau TE, Roy JP, Hunter GR. Diet-induced changes in intraabdominal adipose tissue and CVD risk in American women. Obesity (Silver Spring) 2009;17:2169-2175
36. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887
37. Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebocontrolled study of the effect of sustainedrelease bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008; 28:302-307
38. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustainedrelease bupropion in depression: results of three clinical trials. Clin Ther 1999;21: 454-463
39. Glucophage (metformin hydrochloride) tablets [package insert]. Bristol-Meyers Squibb, 2009
40. Smith SR, Weissman NJ, Anderson CM, et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256